Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S
Department of Urology, Kobe University School of Medicine, Japan.
Urology. 1999 Feb;53(2):302-7. doi: 10.1016/s0090-4295(98)00486-5.
To determine whether the serum vascular endothelial growth factor (VEGF) level in patients with urothelial cancer could be used as a predictor of recurrence and disease progression.
Serum levels of VEGF in 51 healthy controls and 135 patients with urothelial cancer (81 superficial and 54 invasive cancers) were measured using a sandwich enzyme immunoassay, and the results were analyzed with respect to several clinicopathologic factors.
Significant differences in the serum VEGF level were observed between healthy controls and patients with superficial urothelial cancer (34+/-12 pg/mL versus 49+/-27 pg/mL, P<0.001) and between healthy controls and patients with invasive cancer (34+/-12 pg/mL versus 51+/-35 pg/mL, P<0.001), whereas there was no significant difference in the serum VEGF level between superficial and invasive cancers (49+/-27 pg/mL versus 51+/-35 pg/mL, P = 0.31). Among patients with superficial cancer, the disease-free survival rate of patients with elevated serum levels of VEGF was significantly lower than that of patients with normal levels (P<0.05). The progression-free survival rate of superficial cancer patients with elevated serum levels of VEGF was also significantly lower than that of patients with normal levels (P<0.01). In addition, Cox's multivariate analysis revealed that the elevation of serum VEGF level was strongly associated with disease-free survival and progression-free survival in patients with superficial cancer (P<0.05).
The results of this study suggest that the elevation of serum VEGF level could be used as a new independent predictor of recurrence and disease progression in patients with superficial urothelial cancer.
确定尿路上皮癌患者血清血管内皮生长因子（VEGF）水平是否可作为复发和疾病进展的预测指标。
采用夹心酶免疫分析法检测51名健康对照者和135例尿路上皮癌患者（81例表浅癌和54例浸润癌）的血清VEGF水平，并结合多项临床病理因素进行分析。
健康对照者与表浅尿路上皮癌患者血清VEGF水平存在显著差异（34±12 pg/mL对49±27 pg/mL，P<0.001），健康对照者与浸润癌患者血清VEGF水平也存在显著差异（34±12 pg/mL对51±35 pg/mL，P<0.001），而表浅癌与浸润癌患者血清VEGF水平无显著差异（49±27 pg/mL对51±35 pg/mL，P = 0.31）。在表浅癌患者中，血清VEGF水平升高患者的无病生存率显著低于水平正常者（P<0.05）。血清VEGF水平升高的表浅癌患者的无进展生存率也显著低于水平正常者（P<0.01）。此外，Cox多因素分析显示，血清VEGF水平升高与表浅癌患者的无病生存和无进展生存密切相关（P<0.05）。
本研究结果提示，血清VEGF水平升高可作为表浅尿路上皮癌患者复发和疾病进展的新的独立预测指标。
